Ausdal Financial Partners Inc. Sells 6,500 Shares of Acelyrin, Inc. (NASDAQ:SLRN)

Ausdal Financial Partners Inc. cut its stake in Acelyrin, Inc. (NASDAQ:SLRN) by 33.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 12,800 shares of the company’s stock after selling 6,500 shares during the quarter. Ausdal Financial Partners Inc.’s holdings in Acelyrin were worth $40,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. American Century Companies Inc. raised its stake in shares of Acelyrin by 146.0% in the fourth quarter. American Century Companies Inc. now owns 78,868 shares of the company’s stock valued at $248,000 after acquiring an additional 46,802 shares during the period. Intech Investment Management LLC raised its position in Acelyrin by 71.0% in the 4th quarter. Intech Investment Management LLC now owns 26,587 shares of the company’s stock worth $83,000 after purchasing an additional 11,040 shares during the period. Franklin Resources Inc. lifted its stake in Acelyrin by 36.9% in the third quarter. Franklin Resources Inc. now owns 128,591 shares of the company’s stock worth $634,000 after purchasing an additional 34,642 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Acelyrin during the third quarter valued at approximately $50,000. Finally, Barclays PLC grew its stake in shares of Acelyrin by 208.8% during the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after buying an additional 65,188 shares during the last quarter. 87.31% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Acelyrin

In other news, CEO Mina Kim sold 17,986 shares of the business’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.74, for a total value of $49,281.64. Following the completion of the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at approximately $1,840,603.22. The trade was a 2.61 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 13.60% of the company’s stock.

Acelyrin Trading Down 1.5 %

Shares of SLRN stock opened at $2.60 on Friday. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25. The stock has a fifty day simple moving average of $2.34 and a two-hundred day simple moving average of $3.75. The stock has a market capitalization of $261.85 million, a price-to-earnings ratio of -1.06 and a beta of 1.27.

Acelyrin (NASDAQ:SLRN) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.86) by $0.07. Research analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on SLRN shares. Citigroup decreased their price target on Acelyrin from $6.00 to $3.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. HC Wainwright lowered their target price on shares of Acelyrin from $8.00 to $6.00 and set a “neutral” rating for the company in a research note on Tuesday, January 7th. Finally, Wells Fargo & Company decreased their price objective on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a report on Wednesday, December 11th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $9.60.

Acelyrin Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.